SIT-047 / Sitryx, Eli Lilly - LARVOL DELTA

Sitryx presents new preclinical data highlighting MTHFD2 as a novel metabolic target in autoimmune disease at ACR Convergence 2025 (GlobeNewswire) - "SIT-047, with first-in-class potential as a disease-modifying treatment for psoriatic arthritis, expected to enter the clinic in 2026....They demonstrate that inhibition of MTHFD2, a mitochondrial enzyme upregulated in inflammatory tissue, resulted in reduced proliferation of B and CD4⁺ T cells while preserving overall cell viability, underscoring dual action on both T and B cell arms of adaptive immunity. The studies further showed that MTHFD2 inhibition reduced antigen-specific immune responses and supressed pathogenic cytokine production, reducing severity of autoimmune inflammation in preclinical models."

New trial • Preclinical • Immunology • Psoriatic Arthritis

Sitryx nominates SIT-047, a novel, oral MTHFD2 inhibitor, for clinical development in psoriatic arthritis (GlobeNewswire) - "Sitryx Therapeutics...today announces the nomination of SIT-047, a novel, oral MTHFD2 inhibitor, as the latest development candidate from its proprietary pipeline to progress to regulatory non-clinical studies to support a Clinical Trial Authorisation (CTA)....SIT-047 has demonstrated strong efficacy in preclinical models and represents a promising precision immunometabolic approach to immune modulation."

Pipeline update • Preclinical • Psoriatic Arthritis